CLLS Stock Analysis: Buy, Sell, or Hold?
CLLS - Cellectis S.A. American Depositary Shares
$3.24
-0.08 (-2.41%)
âŧ
5d:
-4.71%
30d:
+20.45%
90d:
+5.88%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Get Alerted When CLLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CLLS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CLLS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CLLS is currently trading at $3.24, which is considered slightly high relative to its 30-day fair value range of $2.82 to $3.34.
Technical Outlook: Technically, CLLS is in a strong downtrend. Immediate support is located at $3.10, while resistance sits at $3.60.
Market Sentiment: CLLS scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.60 (+134.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLLS is in a strong downtrend. Immediate support is located at $3.10, while resistance sits at $3.60.
Market Sentiment: CLLS scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.60 (+134.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.82 -
$3.34
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (34/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 134.6% below Wall St target ($7.60)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.82 -
$3.34
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.10
Resistance Level
$3.60
Current Trend
Strong Downtrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.94
Wall Street Target
$7.60
(+134.6%)
Revenue Growth (YoY)
-62.1%
Profit Margin
-102.3%
Share & Embed Analysis
Last updated: September 04, 2026 6:42 PM ET
Data refreshes hourly during market hours. Next update: 7:42 PM
Data refreshes hourly during market hours. Next update: 7:42 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 46 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1176 | 44 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 27 SELL |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 57 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$133 | 51 HOLD |
